יחס חוב לטווח קצר להון עצמי: Intra-Cellular Therapies, Inc. (ITCI)

The competitive advantage of Intra-Cellular Therapies (ITCI) is growing due to surging demand for bipolar disorder therapies and patent protection extending through 2030. Historical price action reflects the 0.00 metric. Business revenues are based on the sale of Caplyta for the treatment of depression and schizophrenia in the US. Operational stability relies on a robust intellectual property portfolio and innovative therapy methods for severe psychiatric pathologies.

To isolate fundamental stability from market noise, analyzing the share of short-term liabilities within the equity structure is critical, as low values confirm the absence of liquidity risk. The short-term debt-to-equity dynamics of Intra-Cellular Therapies (ITCI) demonstrate the company's ability to fund laboratory robotization and the implementation of clinical data processing software systems without excessive leverage, ensuring financial stability while scaling its technology stack.